BALTIMORE – The US FDA's generics program has reached a long-sought milestone: a steady state in its workload.
Office of Generic Drugs Director Kathleen Uhl made the pronouncement Sept. 7 during a presentation at the Association for Accessible Medicines' GRx Biosims conference. It has taken the agency nearly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?